申请人:Janssen Pharmaceutica, N.V.
公开号:US05824682A1
公开(公告)日:1998-10-20
The present invention is concerned with compounds of formula ##STR1## the pharmaceutically acceptable acid addition salts thereof, and the stereochemically isomeric forms thereof, wherein R.sup.1 is hydrogen or C.sub.1-6 alkyl; R.sup.2 is hydrogen or C.sub.1-6 alkyl; R.sup.3 is hydrogen or C.sub.1-6 alkyl; R.sup.4 is hydrogen, halo, C.sub.1-6 alkyl, hydroxy, C.sub.1-6 alkyloxy, aryloxy or arylmethoxy; R.sup.5 and R.sup.6 designate R.sup.5a and R.sup.6a wherein R.sup.5a and R.sup.6a taken together form a bivalent radical; or R.sup.5 and R.sup.6 can designate R.sup.5b and R.sup.6b wherein R.sup.5b is hydrogen and R.sup.6b is a heterocycle or an optionally substituted alkenyl or alkynyl group; or R.sup.5 and R.sup.6 designate R.sup.5c and R.sup.6c, wherein R.sup.5c and R.sup.6c are hydrogen, halo, C.sub.1-6 alkyl, C.sub.3-6 alkenyl, C.sub.3-6 alkynyl, hydroxy, C.sub.1-6 alkyloxy, cyano, aminoC.sub.1-6 alkyl, carboxyl, C.sub.1-6 alkyloxycarbonyl, nitro, amino, aminocarbonyl, C.sub.1-6 alkylcarbonylamino, or mono-di(C.sub.1-6 alkyl)amino; Q is a heterocyclic ring containing at least one nitrogen atom or a radical of formula ##STR2## pharmaceutical compositions, preparations and use as a medicine are also described.
本发明涉及具有式##STR1##的化合物,其药学上可接受的酸加成盐,以及其立体化学异构形式,其中R1是氢或C1-6烷基;R2是氢或C1-6烷基;R3是氢或C1-6烷基;R4是氢、卤素、C1-6烷基、羟基、C1-6烷氧基、芳氧基或芳基甲氧基;R5和R6表示R5a和R6a,其中R5a和R6a一起形成二价基团;或者R5和R6可以表示R5b和R6b,其中R5b是氢,R6b是杂环或任选取代的烯基或炔基;或者R5和R6表示R5c和R6c,其中R5c和R6c是氢、卤素、C1-6烷基、C3-6烯基、C3-6炔基、羟基、C1-6烷氧基、氰基、氨基C1-6烷基、羧基、C1-6烷氧羰基、硝基、氨基、氨基羰基、C1-6烷基羰基氨基,或单-二(C1-6烷基)氨基;Q是含有至少一个氮原子的杂环或式##STR2##的基团;还描述了药物组合物、制剂及其作为药物的用途。